National guidelines for the management of HIV-1 in pregnancy

Irish Medical Journal

Volumn 99, Issue 5, 2006, Pages

  Lyons, F ^a   Mulcahy, F ^a   Coulter Smith, S ^a   Butler, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMINOTRANSFERASE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIPID; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; ZIDOVUDINE;

ANEMIA; ARTICLE; BREAST FEEDING; CD4+ T LYMPHOCYTE; CLINICAL PROTOCOL; DELIVERY; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ERUPTION; DYSLIPIDEMIA; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; IRELAND; LABOR; LACTIC ACIDOSIS; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PREGNANCY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PREMATURITY; PRENATAL CARE; PRESCRIPTION; RISK ASSESSMENT; SCREENING; TERATOGENICITY; TREATMENT REFUSAL; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS REPLICATION;

EID: 33747687132     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Clarke S, Butler K, Bergin C, Lyons F, Sheehan G, Horgan M, Mulcahy F. National Guidelines for the activemanagement of HIV in pregnancy. Ir Med J 2001 May 94(5): 137-140
2. Kourtis A, Butlerys S, Nesheim S et al. Understanding the timing of HIV transmission from mother to infant. JAMA. 2001; 285(6): 709 712
3. Ioannidis J.P.A., Abrams E.J., Ammann A. et al. Perinatal transmission of Human Immunodeficency Virus Type 1 bypregnant women with RNA virus loads <1000copies/ml. J Infect Dis 2001:183:539-545
4. The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factorbutnot the only one. AIDS 1999; 13: 1377-1385
5. The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: ameta-analysis from 15 prospective cohort studies. AIDS 2001; 15: 357-368
6. www.ndsc.ie
7. Connor E.M., Sperling R.S., Gelber R. et al. Reduction of maternal-infant transmission of HIV type-1 with Zidovudinetreatment. N Engl J Med 1994 331 (18) 1173-80
8. Cooper Er, Charurat M, Mofenson L, Hanson I, Pitt J, Diaz C, Hayano K, Handelsman R, Smeriglio, Hoff R, Blattner W; Women and Infants Transmission Study Group. Combination antiretroviral strategies for the treatment and prevention ofperinatal HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29(5): 484-494
9. www.aidsinfo.nih.gov. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents -November 10, 2003
10. www.bhiva.org British HIV Association (BHIVA) guidelines for the treatment of HIV infected adults withantiretroviral therapy. July 2003
11. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1positive women taking antiretroviral medication. Sex Transm Infect 2002; 78(1): 58-59
12. Bristol-Myers Squibb Company. Healthcare provider important drug warning letter. January 5, 2001
13. Lyons F, Mc Geary A et al. Nevirapine tolerability in HIV infected women in pregnancy A word of caution. 2nd IASconference on HIV pathogenesis and treatment. Paris, France July 2003 (late breaker)
14. For the PACTG 1022 Study Team. Maternal Toxicity with Continuous Nevirapine in Pregnancy: Results From PACTG 1022. J Acquir Immune Defic Syndr. 2004 Jul 1; 36(3):772-776
15. Stern JO, Robinson PA, Love J et al. A comprehensive safety analysis of nevirapine in different populations ofHIV-1 infected patients. J Acquir Immune Defic Syndr. 2003; 34: S21-S33.
16. Lorenzi P., Masserey S.V., Laubereau B. et al and the Swiss HIV cohort study, the Swiss Collaborative HIV and pregnancy study, and the Swiss neonatal HIV study. Antiretroviral therapies in pregnancy: maternal, foetal, andneonatal effects. AIDS 1998:12:F241-7
17. Tuomala R, Shapiro D, Mofensen L et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346(24): 1863-1870).
18. www.BHIVA.org. Guidelines for the management of HIV infection in pregnant women and the prevention ofmother-to-child transmission. BHIVA 4th May 2001
19. www.aidsinfo.nih.gov Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in PregnantHIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States-November 26, 2003
20. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV.N Engl J Med. 2002 Aug 8;347(6):385-94.
21. Lyons F, Coughlan S, Byrne C, Hopkins S, Hall W, Mulcahy F. Emergence of antiretroviral resistance in HIV-positivewomen receiving combination antiretroviral therapy in pregnancy. AIDS 2005 Jan 3;19(1): 63-7
22. Stringer J.S.A., Rouse D.J., Goldenberg R.L. Prophylactic caesarean section for the prevention of perinatal HIVtransmission. JAMA 1999:281:20:1946-50
23. The European mode of delivery collaboration. Elective caesarean section versus vaginal delivery in prevention ofvertical HIV-1 transmission: a randomised clinical trial. Lancet 1999:353:1035-39
24. The international perinatal HIV group. The mode of delivery and the risk of vertical transmission of HIV type 1. NEng J Med 1999;340:977-87
25. ACOG educational bulletin. Assessment of fetal lung maturity. Number 230, November 1996. Committee on Educational Bulletins of the American College of Obstetricians and Gynaecologists. Int J Gynaecol Obstet. 1996; 56 (2):191-198)
26. OMeara M, Goode M, Hayes E et al. Simplification of the neonatal component of regimens to prevent perinatalHIVtransmission. In: Program and abstracts of the tenth conference on retroviruses and opportunistic infections, Boston2003 (Abstract P70
27. Blanche S, Mandelbrot L, Rustin P et al. Persistent mitochondrial dysfunction and perinatal exposure toantiretroviral nucleoside analogues. Lancet 1999; 354: 1084-1089
28. Butlerys M, Nesheirn S, Abrams E et al. Lack of evidence of mitochondrial dysfunction in the offspring HIV-infected women: retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDSCollaborative Study. Ann NY Acad Sci 2000; 918: 212-221
29. Guay LA, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudineforthe prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET012 randomised trial. Lancet1999:354; 795-802
30. Cunningham CK, Chaix ML, Rekacewicz C et al. Development of resistance mutations in women receiving standardantiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficency virus type ltransmission: a substudy of paediatric AIDS clinical trial group protocol 316. J Infect Dis 2002: 186(2); 181-188
31. Eshelman SH, Mracna M, Guay L et al. Selection and fading of resistance mutations in women and infants receivingnevirapine to prevent HIV-1 vertical transmission (HIVNET012). AIDS 2001: 15(15); 1951-1957